Feds Lawsuit 3.35billion $$$

Discussion in 'Alcon' started by Anonymous, Jul 2, 2015 at 6:22 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    surprised no comments on the Fed's 3.35 Billion dollar lawsuit

    that is a lot of pazeo you will have to sell to make up the cost
     

  2. Anonymous

    Anonymous Guest

    It's about time
     
  3. Anonymous

    Anonymous Guest

    More job cuts at Stepchild Alcon
     
  4. Anonymous

    Anonymous Guest

    Let's hope the share holders wake up and demand some accountability.
     
  5. Anonymous

    Anonymous Guest

    There is no accountability in this corrupt company. I wouldn't even classify Novartis/Alcon as a healthcare company.
     
  6. Anonymous

    Anonymous Guest

    Sounds like some people skipped their Values and Behaviors plateau.
     
  7. Anonymous

    Anonymous Guest

    Pretty sure senior management has never been trained on values and behaviors. Could they even name them if asked?
     
  8. Anonymous

    Anonymous Guest

    Of course they can name the. There's passing the buck. Lack of accountability. Lying. Cheating. Stealing samples for home use. Playing on the phone. Late for meetings. Lack of actual functioning knowledge for their jobs. Not being able to communicate. Ass kissing. And finally general uselessness. This is how you evaluate yourself as a manager at Alcon in Fort Worth, anyway.
     
  9. Anonymous

    Anonymous Guest

    The whistle blower law seems to be working as intended. The person that tipped off the Feds will get an excellent pay out and just enjoy life.
     
  10. Anonymous

    Anonymous Guest

    You think there is only one Whistleblower at Alcon? Try again Buddy.

    They are all lining up, as Management has turned a blind eye for far too long.

    The Division will implode and the realisation will rapidly dawn on Shareholders that Novartis paid far "too much" for the Global Leader in Fraudcare. It is definitely a "negative zero" investment, especially when the Feds start sharpening their pencils.

    Let's see Novartis embark on a "divestment strategy" in the near future.